Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:33 2024-07-15 am EDT			5-day change	1st Jan Change
258.7 ^CHF	+1.53%		+6.16%	+5.81%

Jul. 15	ROCHE HOLDINGS AG : Sell rating from Goldman Sachs	ZD
Jul. 15	ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank	ZD

CHEPLAPHARM Arzneimittel GmbH acquired Global rights to Roaccutan from Roche Holding AG (SWX : ROG).

January 17, 2024

CHEPLAPHARM Arzneimittel GmbH acquired Global rights to Roaccutan from Roche Holding AG (SWX : ROG) on January 18, 2024.

CHEPLAPHARM Arzneimittel GmbH completed the acquisition of Global rights to Roaccutan from Roche Holding AG (SWX : ROG) on January 18, 2024.

Latest news about Roche Holding AG

ROCHE HOLDINGS AG : Sell rating from Goldman Sachs	Jul. 15	ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank	Jul. 15	ZD
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating	Jul. 11	ZD
DexCom, Inc. : A Must-Have Tool for Diabetes Care	Jul. 10
Markets Powered by Alternating Current	Jul. 10
ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating	Jul. 10	ZD
ROCHE HOLDINGS AG : UBS gives a Neutral rating	Jul. 10	ZD
SIX to Cap SLI Index Weight of Nestle, Novartis Roche, UBS	Jul. 10	MT
Swiss Market Index Closes in the Red; Roche Rises	Jul. 09	MT
Mixed feelings	Jul. 09
ROCHE HOLDINGS AG : UBS remains Neutral	Jul. 09	ZD
Roche: CE marking in diabetes monitoring	Jul. 09	CF
Roche Secures CE Mark for AI-powered Continuous Glucose Monitoring Device	Jul. 09	MT
Roche Receives CE Mark for Its AI-Enabled Continuous Glucose Monitoring Solution Offering Critical Predictions to People Living with Diabetes	Jul. 09	CI
Roche Secures FDA Nod to Relaunch Susvimo in US After Recall	Jul. 08	MT
Roche launches recalled eye implant in US	Jul. 08	RE
Roche Gets FDA Approval to Reintroduce Eye Implant Susvimo to the U.S.	Jul. 08	DJ
Roche: reintroduces Susvimo, FDA validates updates	Jul. 08	CF
Roche reintroduces recalled eye implant in US	Jul. 08	RE
Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration	Jul. 08	CI
Global markets live: Apple, Samsung, Shell, Tesla, KKR...	Jul. 05
Trending : Roche to Halt Lung-Cancer Trials After Treatment Misses Goals	Jul. 05	DJ
ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating	Jul. 05	ZD
Roche: new approval for Vabysmo in the United States	Jul. 05	CF
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating	Jul. 05	ZD

Chart Roche Holding AG

Duration

Period

More charts

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

2024-07-23 - American Society of Retina Specialists Meeting

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 11:50 am EDT

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

258.7 CHF

Average target price

274 CHF

Spread / Average Target

+5.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	+5.81%	234B
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.42%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+14.19%	244B
NOVARTIS AG	+16.77%	226B
AMGEN INC.	+14.63%	177B
PFIZER, INC.	+1.08%	165B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

CHEPLAPHARM Arzneimittel GmbH acquired Global rights to Roaccutan from Roche Holding AG (SWX : ROG).

EPS Revisions